Todos Medical Appoints Valentino Smith, MBA, Vice President of Marketing

0
  • Company Retains iiiNTENT SAAS Artificial Intelligence Marketing Department for Tollovid® and Tollovid Daily ™ 3CL Protease Inhibitor Dietary Supplement Products

NEW YORK, NY and TEL AVIV, Israel, December 20, 2021 (GLOBE NEWSWIRE) – via NewMediaWire – Todos Medical Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the appointment of Mr. Valentino Smith, MBA, as vice president of marketing. Mr. Smith brings more than ten years of marketing experience to Todos, including physical and digital marketing for consumer packaged products, health services and information, over-the-counter (OTC) supplements, and pharmaceuticals.

“I am very happy to join Todos, especially as the Company begins to market Tollovid and Tollovid Daily, and as the Company prepares to collaborate with regulatory agencies around the world regarding Tollovir ™, the oral antiviral drug candidate. of the Society for COVID-19 is currently under development. a phase 2 inpatient trial, ”said Valentino Smith, MBA, vice president of marketing at Todos. “I see tremendous growth opportunities and look forward to continuing efforts just as we see a massive increase in the need for high throughput, fast turnaround SARS-CoV-2 PCR assays as the Omicron variant grows. installs across the United States. “

Mr. Valentino joins Todos with over 10 years of healthcare marketing experience. Most recently, Mr. Valentino was responsible for omnichannel engagement for Novartis Oncology, where he developed media plans and led the execution of global digital solutions for the early launch of Piqray. Prior to Novartis, Mr. Smith was Associate Director of Global Marketing for Merck, where he led plans for scientific engagement with medical affairs by identifying new ways to interact and partner with healthcare professionals and diverse patient advocacy groups. Prior to Merck, Mr. Smith held various marketing positions at WebMD and McCann Healthcare / Gray Healthcare Group. Mr. Valentino is currently Adjunct Assistant Professor of Marketing at Long Island University and received his undergraduate and MBA degrees from Long Island University.

At the same time as this announcement, the Company retained the services of iii INTENT, an artificial intelligence digital marketing as a service (SAAS) software to help commercialize 3CL protease inhibitor dietary supplement immune support products Tollovid® and Tollovid Daily ™.

“We are very pleased to partner with Todos Medical on pending marketing campaigns for Tollovid and Tollovid Daily,” said Chase Gibson, co-CEO of iiiNTENT. “This appears to be an extremely timely product and we believe we can drive substantial traffic with high conversion rates given the highly motivated personalities we intend to target. “

“We are now in growth mode for our business products and services, from our Tollovid & Tollovid Daily products to our COVID testing services that we currently offer from our Provista Diagnostics CLIA / CAP lab,” said Gerald E. Commissiong, President and CEO of Todos Medical. “Valentino’s vast experience in commercializing key health products at the highest levels has prepared him for challenges by helping us engage with clients and clients for our diverse range of products and services that address key bottlenecks in the business. strangulation that currently exist in our health care system. We are also very excited to work with iiiNTENT to drive the growth of our Tollovir product brand, as we believe this could be a significant driver of revenue growth by 2022. ”

For more information on Provista’s parent company, Todos Medical, please visit www.todosmedical.com. For more information on Provista Diagnostics’ CLIA / CAP certified lab, please visit www.provistadx.com.

About Todos Medical Ltd.

Founded in Rehovot, Israel, with offices in New York, Todos Medical Ltd. (OTCQB: TOMDF) designs vital diagnostic solutions for the early detection of a variety of cancers. In 2021, Todos completed the acquisition of U.S. medical diagnostics company Provista Diagnostics, Inc. to secure the rights to its CLIA / CAP certified lab based in Alpharetta, Georgia, which currently performs COVID PCR testing and blood of Videssa® breast cancer from Provista. test. The company’s state-of-the-art and patented Todos Biochemical Infrared Analyzes (TBIA) is a proprietary cancer screening technology using peripheral blood analysis that deploys a comprehensive examination of the influence of cancer on the immune system, at the search for biochemical changes in mononuclear cells in blood and plasma. The two cancer screening tests developed in-house by Todos, TMB-1 and TMB-2, have received CE marking in Europe. Todos is focused on commercializing Videssa and will commercialize the TBIA tests thereafter.

Todos has entered into a joint venture with NLC Pharma targeting diagnostic and testing solutions to deal with the COVID-19 pandemic. The Joint Venture continues to develop diagnostic tests targeting 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses. The Company’s exclusive therapeutic candidate, Tollovir ™, is currently in a Phase 2 clinical trial to treat hospitalized COVID-19 patients in Israel, and is preparing to launch phase 2/3 clinical trials for inpatients and outpatients in Israel.

Todos is also developing blood tests for the early detection of neurodegenerative diseases, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test ™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBL) and monocytes to resist exogenous mitogenic stimulation that prompts them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant reentry of the cell cycle by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos also distributes certain (COVID-19) testing materials and supplies to CLIA certified laboratories in the United States. The products cover multiple suppliers of PCR test kits, extraction kits, automation equipment and supplies, as well as COVID-19 antibody and antigen test kits.

For more information, please visit https://www.todosmedical.com/.

Forward-looking statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our clinical development programs and expected clinical trials. These forward-looking statements are based solely on management’s current expectations, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements, including risks and uncertainties associated with progress, timing, cost and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to secure the additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in forward-looking statements: changes in technology and market requirements; delays or obstacles in starting our clinical trials; changes in legislation; the inability to develop and introduce new technologies, products and applications in a timely manner; the lack of validation of our technology as we progress and the lack of acceptance of our methods by the scientific community; failure to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties which may develop with our process; a higher cost of the final product than expected; loss of market share and price pressure resulting from competition; and laboratory results which do not translate into equally good results under actual conditions, which could cause actual results or performance to differ materially from those contemplated in such forward-looking statements. Unless otherwise required by law, Todos Medical undertakes no obligation to publish revisions of these forward-looking statements to reflect events or circumstances subsequent to the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the United States Securities and Exchange Commission.

Contact Companies and Investors:
Richard galterio
To do Medical
732-642-7770
[email protected]

Main logo


Source link

Share.

Comments are closed.